Full-Time

Manager – Onehub External Partnerships

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$109.5k - $208.5k/yr

+ Long-term incentive program

North Chicago, IL, USA

Hybrid

Bachelor's

Category
Project & Program Management (1)
Business & Strategy
Required Skills
Data Analysis

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A bachelor's degree is required.
  • At least 6 years of experience in vendor management, consulting, contracting, pricing, procurement, external partnerships, patient services, access support, or related commercial operations is required.
  • Demonstrated program management experience, including managing multiple concurrent projects, project planning, and financial or budget schedule tracking, is required.
  • Proven ability in cross-functional leadership and driving alignment across diverse stakeholder groups in a matrixed organization is required.
  • Excellent stakeholder communication skills, including the ability to create executive-level updates, program dashboards, and status reports, are required.
Responsibilities
  • Provide oversight for OneHUB vendors supporting AbbVie's Access and Affordability programs across OneHUB and AbbVie Patient Services.
  • Manage day-to-day vendor oversight, including service-level agreements, quality standards, compliance requirements, and evolving business needs.
  • Catalog service-level agreements and metrics across vendors to identify standardization opportunities.
  • Partner with AbbVie Patient Services and brand stakeholders to translate strategic priorities into operational execution.
  • Identify cross-vendor performance enhancement opportunities to optimize patient experience, efficiency, and program effectiveness.
  • Participate in requests for proposals, contract redlining, contract negotiations, and pricing discussions.
  • Evaluate proposals and create pricing simulations that meet business objectives.
  • Create a blueprint for the external partnership vertical, including current vendors, contracts, and renewal cycles.
  • Establish ways of working with stakeholders and create a governance model.
  • Drive multiple concurrent vendor and patient services initiatives from planning through execution, ensuring on-time delivery, budget adherence, and stakeholder communication.
  • Oversee hub vendor performance across multiple partners.
  • Ensure adherence to contractual obligations, service-level agreements, key performance indicators, quality standards, and compliance requirements.
  • Develop and maintain governance frameworks, reporting structures, and performance review cadences.
  • Conduct business reviews with external hub vendors.
  • Identify performance gaps and direct corrective action plans with clear accountability and measurable outcomes.
  • Define the scope of requests for proposals and work with category management to translate requirements and drive the process.
  • Create guidance for proposal scoring, prepare for oral presentations, and organize vendor site visits.
  • Lead cross-functional efforts to align Patient Services, Brand, Information Technology, and Compliance teams around vendor performance goals and program milestones.
  • Track open action items, escalate blockers, and ensure accountability across vendor and internal stakeholder teams.
  • Monitor vendor financial performance and resource utilization.
  • Maintain budget and financial schedule tracking for vendor programs, monitor spend against planned budgets, and flag variances for resolution.
  • Identify operational, compliance, and performance risks and implement mitigation strategies.
  • Apply structured risk mitigation planning to surface, assess, and address vendor operational and compliance risks before they affect patient services.
  • Ensure adherence to regulatory and quality standards within patient support operations.
  • Analyze existing vendor programs to identify opportunities and economies of scale that produce financial savings.
  • Analyze request-for-proposal pricing and create price simulations for contract negotiations.
  • Partner with AbbVie Patient Services to understand evolving strategy, patient support models, and brand needs.
  • Translate new product launches, lifecycle changes, and access model updates into operational direction for vendors.
  • Provide performance updates, risk assessments, and strategic recommendations to internal stakeholders.
  • Maintain stakeholder communication through structured reporting, status updates, and executive-level briefings.
  • Ensure vendor capabilities and resource models scale to meet changing business demands.
  • Create clear ways of working with internal stakeholders.
  • Identify opportunities to enhance performance, improve efficiency, and standardize best practices across vendors.
  • Use data and insights to compare performance trends and identify scalable improvement opportunities.
  • Guide vendors on process enhancements, staffing adjustments, workflow redesign, and technology optimization.
  • Drive root cause analysis and mitigation planning for systemic or recurring issues.
  • Apply project planning discipline to vendor improvement initiatives by defining scope, timelines, owners, and success metrics.
  • Lead and develop a team responsible for external vendor relationship management and performance monitoring.
  • Set priorities, accountability standards, and performance expectations.
  • Coach team members to improve vendor management capabilities, analytical rigor, and operational effectiveness.
  • Synthesize vendor data to extract meaningful insights.
  • Manage multiple concurrent projects across the vendor portfolio with clear project plans, milestones, and resource assignments.
  • Organize competing projects and create artifacts defining project scope, scale, and value for internal and external stakeholders.
  • Develop and maintain program schedules and financial tracking tools to monitor progress, budget spend, and resource utilization.
  • Create repositories of vendors and contracts with their service-level agreements, metrics, quality targets, and training targets.
  • Create a quarterly-objective program roadmap for external partnerships.
Desired Qualifications
  • Experience in healthcare, biopharma, patient services, specialty pharmacy, or access support environments is preferred.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
  • AbbVie raised 2026 guidance to $13.87-$14.07 after broad strength across immunology and neuroscience.
  • Rinvoq and Skyrizi both grew above 23% operationally, showing durable post-Humira momentum.

What critics are saying

  • Humira sales fell 36.1% in Q2 2026; biosimilars keep compressing cash flows.
  • Imbruvica dropped 29.4% in Q2 2026, exposing oncology weakness and IRA pricing damage.
  • Apogee dilutes adjusted EPS through 2027; if Skyrizi stalls, AbbVie loses its bridge.

What makes AbbVie unique

  • Skyrizi and Rinvoq delivered $8.0 billion in Q2 2026, replacing Humira.
  • AbbVie completed Apogee on September 3, 2026, adding long-acting immunology assets.
  • Etentamig posted 74% response in Phase 3 multiple myeloma, broadening oncology optionality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 10th, 2026
AbbVie shifts focus from declining Humira to $8B Skyrizi and Rinvoq growth engines

AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.

Yahoo Finance
Sep 9th, 2026
Billionaire hedge fund manager doubles down on AbbVie and Costco dividend stocks

Israel Englander's Millennium Management more than doubled its stakes in AbbVie and Costco during the second quarter. AbbVie's revenue grew 10.2% year-over-year to $17 billion in Q2, driven by immunology drugs Skyrizi and Rinvoq. The company recently acquired Apogee Therapeutics for $10.9 billion in cash and is developing ABBV-295, a monthly weight-loss treatment. AbbVie is a Dividend King with over 50 consecutive years of payout increases. Costco's Q3 fiscal 2026 revenue rose 11.6% to $70.5 billion, with comparable sales up 9.8%. The company has raised dividends for 22 consecutive years. However, Costco shares are down 4% over the past year whilst trading at 40.8 times forward earnings, above the consumer staples average of 21.6 times. Both companies maintain strong fundamentals despite different market challenges.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.